Abstract:Background The SITC Immunotherapy Resistance Taskforce recently defined primary and secondary resistance to anti-PD-1 therapy,1 yet there is little data that compares these two scenarios. In particular, detailed radiological dynamics of the different resistance types remain undescribed. Methods We performed independent single-blind reevaluations of available radiological image data on a retrospectively assembled cohort of advanced melanoma patients (n=254, median follow-up 31.3 months, figure 1) treated with anti-PD-1 monotherapy initiated between Sept 2009 and Aug 2018 at both Massachusetts General Hospital and Peking University Cancer Hospital. Radiological characteristics and timing at multiple crucial radiological landmarks were analyzed and correlated with each other and with survival. As per the SITC Taskforce, primary resistance was defined as a best response of stable disease (SD) lasting less than six months or disease progression (PD), secondary as PD following an initial partial or complete response (PR/CR) or SD lasting 6 months or greater.1 Results The most dramatic tumor reduction occurred within the first 3 months after anti-PD-1 initiation. A subpopulation of patients who had SD (28.6%, all with tumor shrinkage) experienced further tumor reduction and upgraded to CR/PR and 11.1% of patients with initial PR upgraded to CR. No patients without tumor shrinkage at the initial evaluation ultimately responded. Baseline tumor burden, response depth, timing of maximal response and PD pattern demonstrated great variation and were significantly correlated with each other and with survival. In multivariate analyses, deeper response depth was independently associated with a less widespread progression pattern, less involved organs, smaller target lesion size and slower tumor growth rate (all P≤.001) at PD, and longer post progression survival (PPS) (P=0.005). Compared to primary resistance, secondary resistance was correlated with less broad progression pattern, less tumor burden and slower tumor growth (all P≤.001). Patients with secondary resistance were more likely to receive further local/regional therapy (46.5% vs. 30.9%, P=0.07) rather than systemic therapy (27.9% vs. 56.9%, P<0.001), yet had a significantly longer PPS (HR 0.503, 95% CI, 0.288–0.879, P=0.02). Median PPS was not reached (95% CI, 11.8 months to not reached) for patients with secondary resistance and was 10.3 months (95% CI, 7.7–16.1) for patients with primary resistance (figure 2). Conclusions Radiological dynamics were heterogeneous, yet significantly correlated with survival. Patterns of progression and PPS of the SITC Immunotherapy Resistance Taskforce defined primary and secondary resistance are different. This distinction may be important for the design of clinical trials targeting a PD-1 resistant population. Ethics Approval This study has been conducted in compliance with local Institutional Review Board policies. Consent NA. Reference Kluger H, Tawbi H, Ascierto M, et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. J Immunother Cancer. 2020; 8:3000398.

Tumor Growth Rate As an Early Indicator of the Efficacy of Anti-Pd-1 Immunotherapy in Advanced Melanoma.

Pre-Treatment Tumor Growth Rate Predicts Clinical Outcomes of Patients With Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD-1/PD-L1 Therapy

Early On-Treatment Tumor Growth Rate (EOT-TGR) Determines Treatment Outcomes of Advanced Non-Small-cell Lung Cancer Patients Treated with Programmed Cell Death Protein 1 Axis Inhibitor.

Tumor Mutational Burden Identifies Chemorefractory Gastric Cancer with Overall Survival Advantage after Receiving Toripalimab, a PD-1 Antibody.

Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study

The maximum tumor growth rate predicts clinical outcomes of patients with small-cell lung cancer undergoing first-line chemotherapy plus immune-checkpoint inhibitor therapy

228 Radiological Dynamics and Resistance Types in Patients with Advanced Melanoma Treated with Anti-Pd-1 Monotherapy

Baseline Lesion Number As an Efficacy Predictive and Independent Prognostic Factor and Its Joint Utility with TMB for PD-1 Inhibitor Treatment in Advanced Gastric Cancer

Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy

Pre-treatment Tumor-Specific Growth Rate As a Temporal Biomarker That Predicts Treatment Failure and Improves Risk Stratification for Oropharyngeal Cancer.

Prognostic Significance of Tumor Growth Rate (TGR) in Patients with Huge Hepatocellular Carcinoma Undergoing Transcatheter Arterial Chemoembolization

Tumor Growth Rate in Spinal Giant Cell Tumors of Bone and Association With the Immune Microenvironment and Denosumab Treatment Responsiveness: A Multicenter Study

Impact of response patterns for patients with advanced acral melanoma treated with anti-programmed death-1 monotherapy

Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis

Elevated Peripheral Blood Neutrophil-to-lymphocyte Ratio is Associated with an Immunosuppressive Tumour Microenvironment and Decreased Benefit of PD-1 Antibody in Advanced Gastric Cancer

Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer

The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis

High neutrophil‐to‐lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD‐1 inhibitor monotherapy

The Efficacy of Anti-Pd-1 Combined with Temozolomide in Unresectable, Advanced Melanoma from One Center.

Primary Tumor Characteristics as Biomarkers of Immunotherapy Response in Advanced Melanoma: A Retrospective Cohort Study

Elevated Neutrophil-to-Lymphocyte Ratio is Associated with Poor Outcomes for Melanoma Patients Treated with PD-1 Inhibitor or Chemotherapy in a Chinese Population.